Unknown

Dataset Information

0

Pharmacokinetics of surotomycin from phase 1 single and multiple ascending dose studies in healthy volunteers.


ABSTRACT: Surotomycin, a novel, orally administered, cyclic, lipopeptide antibacterial in development for the treatment of Clostridium difficile-associated diarrhea, has demonstrated minimal intestinal absorption in animal models.Safety, tolerability, and plasma pharmacokinetics of single and multiple ascending oral doses (SAD/MAD) of surotomycin in healthy volunteers were characterized in two randomized, double-blind, placebo-controlled, phase 1 studies.Participants were sequentially enrolled into one of four SAD (500, 1000, 2000, 4000 mg surotomycin) or three MAD (250, 500, 1000 mg surotomycin twice/day for 14 days) cohorts. Ten subjects were randomized 4:1 into each cohort to receive surotomycin or placebo. Surotomycin plasma concentrations rose as dose increased (maximum plasma concentration [Cmax]: 10.5, 21.5, 66.6, and 86.7 ng/mL). Systemic levels were generally low, with peak median surotomycin plasma concentrations observed 6-12 h after the first dose. In the MAD study, surotomycin plasma concentrations were higher on day 14 (Cmax: 25.5, 37.6, and 93.5 ng/mL) than on day 1 (Cmax: 6.8, 11.0, and 21.1 ng/mL for increasing doses), indicating accumulation. In the SAD study, <0.01% of the administered dose was recovered in urine. Mean surotomycin stool concentration from the 1000 mg MAD cohort was 6394 ?g/g on day 5. Both cohorts were well tolerated with all adverse events reported as mild to moderate.Both SAD and MAD studies of surotomycin demonstrated minimal systemic exposure, with feces the primary route of elimination following oral administration; consistent with observations with similar compounds, such as fidaxomicin. Results of these phase 1 studies support the continued clinical development of surotomycin for the treatment of Clostridium difficile-associated diarrhea.NCT02835118 and NCT02835105 . Retrospectively registered, July 13 2016.

SUBMITTER: Chandorkar G 

PROVIDER: S-EPMC5368910 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pharmacokinetics of surotomycin from phase 1 single and multiple ascending dose studies in healthy volunteers.

Chandorkar Gurudatt G   Zhan Qiao Q   Donovan Julie J   Rege Shruta S   Patino Hernando H  

BMC pharmacology & toxicology 20170328 1


<h4>Background</h4>Surotomycin, a novel, orally administered, cyclic, lipopeptide antibacterial in development for the treatment of Clostridium difficile-associated diarrhea, has demonstrated minimal intestinal absorption in animal models.<h4>Methods</h4>Safety, tolerability, and plasma pharmacokinetics of single and multiple ascending oral doses (SAD/MAD) of surotomycin in healthy volunteers were characterized in two randomized, double-blind, placebo-controlled, phase 1 studies.<h4>Results</h4>  ...[more]

Similar Datasets

| S-EPMC7187404 | biostudies-literature
| S-EPMC7891412 | biostudies-literature
| S-EPMC7687182 | biostudies-literature
| S-EPMC10087697 | biostudies-literature
| S-EPMC10014699 | biostudies-literature
| S-EPMC7849180 | biostudies-literature
| S-EPMC10339693 | biostudies-literature
| S-EPMC7485962 | biostudies-literature
| S-EPMC4997859 | biostudies-literature
| S-EPMC4376184 | biostudies-literature